PORTFOLIO

PORTFOLIO COMPANIES

SOCIUM Inc.

  • Chief Executive Officer:
    Hiroshi Kawai

URL:https://socium.co.jp/en/

COMPANY PROFILE

Repurposing and developing pharmaceuticals using a systems biology approach to omics data analysis.

SOCIUM develops pharmaceuticals using a systems biology approach to omics data analysis. In particular, SOCIUM has an original technology for:
・Drug repurposing (drug-repositioning for finding unexpected drugs against disease among commercialized drugs and drug-rescue for finding new indications for dropped drugs)
・ Finding stratification markers (diagnosis marker, clinical trial marker, companion drug, etc.)
SOCIUM supports pharmaceutical companies by providing measurement, analysis, and interpretation services for every step in the drug discovery and development process.

COMPANY STORY

Origin

SOCIUM was established in 2017 with the aim of developing a drug discovery and development platform based on unique gene expression omnibus analysis algorithms developed by Katsuhisa Horimoto in Advanced Industrial Science and Technology (AIST).

Strength

SOCIUM's technology extracts disease-related genes and pathways with high accuracy based on biological significance. Therefore, compared to conventional analysis approaches, SOCIUM can achieve a higher success rate in drug discovery and development

UTEC’s value add

UTEC supports SOCIUM in fund-raising, securing global business alliances and in recruiting management executives.
  • Service flow chart composed with several patents